BYFAVO™ (remimazolam) for injection is a very rapid onset/offset IV benzodiazepine sedative for use during invasive medical procedures lasting 30 minutes or less, such as colonoscopy and bronchoscopy. Its use can induce very rapid onset of sedation and quick post-procedure recovery. It can be reversed with flumazenil to terminate sedation or anesthesia rapidly if necessary.
The efficacy and safety of BYFAVO have been investigated as part of an extensive clinical trial program involving approximately 2,400 volunteers and patients. BYFAVO was approved in the US in July 2020 and US launch is planned in 2H 2020.
Acacia Pharma’s rights to further develop and commercialize BYFAVO are in-licensed from Paion UK Limited pursuant to an assignment from Cosmo Technologies Limited for the US market.
For full safety and prescribing information, please go to www.BYFAVO.com